Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (121-130 of 218) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2019
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trialsA Blauvelt, H Sofen, K Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 1, 2017
Cost-of-illness of psoriasis - results of a German cross-sectional studyD Jungen, M Augustin, A Langenbruch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 9, 2017
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE studyK Reich, M Gooderham, A Bewley, et al.
Skin Pharmacology and Physiology|September 6, 2025
Effects of a gel containing the defined microalgae extract Spiralin® on the skin microbiome and clinical activity in atopic dermatitis - a double-blind, intraindividual vehicle-controlled proof-of-concept studyKristian Reich, Natalie Trettel, Jeremias L K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2019
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 yearsK Reich, A Blauvelt, A Armstrong, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
The British Journal of Dermatology|September 17, 2020
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatmentA Leutz, A Pinter, D Thaçi, et al.
The British Journal of Dermatology|June 29, 2011
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled studyJ-P Ortonne, A F Nikkels, K Reich, et al.
The British Journal of Dermatology|June 2, 2020
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE studyK Reich, J Sullivan, P Arenberger, et al.
Biotechniques|September 1, 1994
A microchip for quantitative detection of molecules utilizing luminescent and radioisotope reporter groupsM Eggers, M Hogan, R K Reich, et al.
Pageof 22

Showing results (121-130 of 218) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2019
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trialsA Blauvelt, H Sofen, K Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 1, 2017
Cost-of-illness of psoriasis - results of a German cross-sectional studyD Jungen, M Augustin, A Langenbruch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 9, 2017
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE studyK Reich, M Gooderham, A Bewley, et al.
Skin Pharmacology and Physiology|September 6, 2025
Effects of a gel containing the defined microalgae extract Spiralin® on the skin microbiome and clinical activity in atopic dermatitis - a double-blind, intraindividual vehicle-controlled proof-of-concept studyKristian Reich, Natalie Trettel, Jeremias L K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2019
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 yearsK Reich, A Blauvelt, A Armstrong, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
The British Journal of Dermatology|September 17, 2020
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatmentA Leutz, A Pinter, D Thaçi, et al.
The British Journal of Dermatology|June 29, 2011
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled studyJ-P Ortonne, A F Nikkels, K Reich, et al.
The British Journal of Dermatology|June 2, 2020
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE studyK Reich, J Sullivan, P Arenberger, et al.
Biotechniques|September 1, 1994
A microchip for quantitative detection of molecules utilizing luminescent and radioisotope reporter groupsM Eggers, M Hogan, R K Reich, et al.
Pageof 22